로딩 중…
지수 로딩 중…
Evolus, Inc.
EOLS· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$6.05+3.60%
2026-08-03
Financials
Valuation Metrics
Evolus, Inc.'s Market Cap is $398M. At end of 2025 it was $429M. Ranked #2889 of 3,112 in US market (top 93%), #1278 of 1,445 on NASDAQ (top 88%), #231 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 86%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $398M | US#2,889/3,112 Sec#231/269 |
| Revenue | $302M | US#2,548/3,112 Sec#96/269 |
| Net Income | $-43M | US—/3,112 Sec—/269 |
| Total Assets | $221M | US#2,963/3,112 Sec#244/269 |
| Net Assets | $19M | US#2,979/3,112 Sec#255/269 |
| Value | ||
| P/B | 20.63x | US#2,820/3,112 Sec#236/269 |
| P/S | 1.32x | US#865/3,112 Sec#14/269 |
| FCF Yield | -10.94% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROA | -19.68% | US#2,768/3,112 Sec#124/269 |
| Op. Margin | -9.56% | US#2,628/3,112 Sec#98/269 |
| Revenue Growth | 6.74% | US#1,565/3,112 Sec#101/269 |
| Financial Health | ||
| Debt Ratio | 1291.43% | US#2,836/3,112 Sec#251/269 |
| Total Debt | $165M | US#2,256/3,112 Sec#101/269 |
| FCF | $-44M | US#2,454/3,112 Sec#111/269 |
| Cash | $50M | US#2,583/3,112 Sec#227/269 |
| Current Ratio | 2.04x | US#1,229/3,112 Sec#225/269 |
| Performance | ||
| 1Y Return | -33.88% | US#2,800/3,112 Sec#230/269 |
| 1M Return | -12.32% | US#2,710/3,112 Sec#188/269 |
| From 52W High | -33.88% | US#2,322/3,112 Sec#176/269 |
| 1Y MDD | -61.52% | US#2,762/3,112 Sec#218/269 |
| Trading | ||
| Volume | 578,496 shares | US#1,951/3,112 Sec#191/269 |
| Trading Value | $3M | US#2,782/3,112 Sec#229/269 |
| Per Share | ||
| EPS | $-0.80 | US—/3,112 Sec—/269 |